menu search

BIIB / FDA grants accelerated approval to Biogen's treatment for rare form of ALS

FDA grants accelerated approval to Biogen's treatment for rare form of ALS
The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.'s BIIB torferson, a treatment for a rare form of amyotrophic lateral sclerosis, or ALS. The accelerated approval program is used to OK drugs for serious conditions with an unmet medical need, where a drug is shown to have an effect on an endpoint that is reasonably likely to predict a clinical benefit to patients. Read More
Posted: Apr 25 2023, 13:52
Author Name: Market Watch
Views: 103199

BIIB News  

Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know

By Zacks Investment Research
October 30, 2023

Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know

The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close. more_horizontal

Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger

By Barrons
October 26, 2023

Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger

Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer's drug. more_horizontal

Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

By Market Watch
October 25, 2023

Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer's treatment Leqembi that may ultimately help bolster uptake of the drug. more_horizontal

Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market

By Zacks Investment Research
October 23, 2023

Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market

The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close. more_horizontal

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

By Reuters
October 23, 2023

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rh more_horizontal

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting

By GlobeNewsWire
October 19, 2023

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upc more_horizontal

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

By Zacks Investment Research
October 17, 2023

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day. more_horizontal

Final Trades: WST, BIIB, SPY & MDT

By CNBC Television
October 11, 2023

Final Trades: WST, BIIB, SPY & MDT

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders. more_horizontal


Search within

Pages Search Results: